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ARTICLE
The anthelmintic praziquantel is a human
serotoninergic G-protein-coupled receptor ligand
John D. Chan1, Pauline M. Cupit2, Gihan S. Gunaratne1, John D. McCorvy3, Yang Yang 1, Kristen Stoltz4,
Thomas R. Webb5, Peter I. Dosa4, Bryan L. Roth3,6,7, Ruben Abagyan2, Charles Cunningham8
& Jonathan S. Marchant1,9,10
Schistosomiasis is a debilitating tropical disease caused by infection with parasitic blood
flukes. Approximately 260 million people are infected worldwide, underscoring the clinical
and socioeconomic impact of this chronic infection. Schistosomiasis is treated with the drug
praziquantel (PZQ), which has proved the therapeutic mainstay for over three decades of
clinical use. However, the molecular target(s) of PZQ remain undefined. Here we identify a
molecular target for the antischistosomal eutomer— (R)-PZQ—which functions as a partial
agonist of the human serotoninergic 5HT2B receptor. (R)-PZQ modulation of serotoninergic
signaling occurs over a concentration range sufficient to regulate vascular tone of the
mesenteric blood vessels where the adult parasites reside within their host. These
data establish (R)-PZQ as a G-protein-coupled receptor ligand and suggest that the
efficacy of this clinically important anthelmintic is supported by a broad, cross species
polypharmacology with PZQ modulating signaling events in both host and parasite.
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Hundreds of millions of people are infected with parasiticworms1. One of the most burdensome infections is theneglected tropical disease schistosomiasis (Bilharzia)
caused by parasitic flatworms of the genus Schistosoma2. Schis-
tosoma infections result from contact with fresh water containing
cercariae, the free-swimming larval stage of the parasite. Cercariae
penetrate the host’s skin, and then transform and mature into
sexualized forms while undergoing a remarkable intravascular
migration to defined vascular beds, where paired male and female
worms complete their maturation and commence egg laying2,3.
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Fig. 1 Resolution of stereoselective (R)-PZQ interaction with human 5-HT2BR. Structures of the PZQ enantiomers: active, a antischistocidal (R)-PZQ (top,
red) and b (S)-PZQ (bottom, blue). c Docking poses of R-PZQ (light red) and S-PZQ (light blue) in the human 5HT2BR. Both isomers of PZQ dock favorably
within the orthosteric pocket of the 5HT2BR crystal structure (Protein Databank Code: 5TVN). The R-isomer shows a better predicted binding score by
0.6 kcal/mole partially due to a more favorable hydrogen bond with the backbone NH group of L209. d Displacement of 3H-LSD binding at human 5-HT2BR
by racemic PZQ ((±)-PZQ 10 µM, purple), (R)-PZQ (5 µM, red) and (S)-PZQ (5 µM, blue) in the PDSP primary screen (n= 5 for all measurements).
e Complete binding displacement curves for 3H-LSD displacement at human 5-HT2BR for SB206553 (black) and (±)-PZQ (purple, n= 5 for both ligands).
f Functional Assays. Ca2+ flux assays showing responses from fluo-4 loaded Flp-In T-REx cells stably expressing 5-HT2AR, 5-HT2BR, or 5-HT2CR at
indicated concentrations of (±)-PZQ (purple, top), (R)-PZQ (red, middle) and (S)-PZQ (blue, bottom; n= 3 for each concentration) in cells expressing
5-HT2AR, 5-HT2BR, or 5-HT2CR
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The debilitating impact of schistosomiasis results from the host’s
immune response to schistosome eggs, deposited in prolific
numbers in the liver, intestine and/or bladder where they elicit
granulomatous inflammation, periportal fibrosis and hyperten-
sion2. Clinical outcomes span gastrointestinal and liver patholo-
gies, genitourinary disease, anemia, malnutrition, and a
heightened risk for comorbidities and HIV transmission. The
associated disease burden encumbers third world economies with
an annual loss of up to 70 million disability-adjusted life years4,5.
Effective drug therapy for schistosomiasis is therefore a key
healthcare priority.
Praziquantel, a tetracyclic tetrahydroisoquinoline derivative
administered as a racemic mixture ((±)-PZQ), is the main drug
therapy for combating schistosomiasis. PZQ causes rapid
paralysis of schistosome musculature and subsequent tegumental
damage that promotes immunological clearance of worms from
the host. The World Health Organization estimates a consider-
able future demand for PZQ of 2 billion tablets over 5 years to
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Fig. 2 (R)-PZQ triggers Ca2+ release via 5-HT2BR. a Representative fluorescence traces from a single experiment where single cells loaded with fluo-4-AM
in a HEK293 cell line prior to (top), or after (bottom) 5-HT2BR induction. Traces show fluorescence ratio following addition of indicated ligands (final
concentrations (±)-PZQ (75 µM), 5-HT (100 nM) or ACh (100 µM)), or vehicle (DMSO, 0.05%). b Pseudocolored confocal images are displayed from the
indicated times (‘1’–‘4’) on associated fluorescence traces as introduced in Fig. 1a. Scalebar, 80 µm. c Peak fluorescence ratio (F/F0, where ‘F’ represents
fluorescence at peak and ‘F0‘ represents fluorescence at time= 0) from cumulative Ca2+ imaging after addition of vehicle, (±)-PZQ, 5-HT or ACh in
uninduced (open bars) or induced cell lines (solid, hatched bars; n≥ 3 independent inductions). Serotonergic antagonists (ritanserin (100 nM, final
concentration), SB204741 (100 nM), or mesulergine (200 nM) were preincubated with induced cells prior to addition of (±)-PZQ (75 µM), 5-HT (10 nM),
or ACh (100 µM). Data represent means± s.e.m. of peak responses averaged from multiple cells (>20) from n≥ 3 independent inductions. d Dose-
response relationship for (±)-PZQ efficacy in cells induced for 5-HT2BR expression (n= 6 for each concentration). e Confocal Ca2+ imaging assays with
(±)-PZQ and resolved enantiomers in uninduced (top row) and 5-HT2BR induced cell lines (bottom three rows). Experiments were performed with racemic
PZQ ((±)-PZQ), and individual (S)-PZQ and (R)-PZQ stereoisomers (5 µM, final concentration). Scalebar, 80 µm. f Processed data set from experiments
such as shown in e representing population mean± s.e.m. (>20 cells) from n≥ 3 independent inductions
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support mass drug administration initiatives5. Clearly, the con-
tinued efficacy of PZQ is essential for this strategy and reports of
PZQ-resistant worm isolates in both laboratory and field high-
light an urgency in resolving how PZQ works6–8. Such knowledge
would catalyze the development of next generation anthelmintics.
Here we employ a variety of experimental approaches to
demonstrate that the antischistosomal eutomer (R)-PZQ acts as a
partial agonist of the human 5-HT2B receptor, establishing (R)-
PZQ as a GPCR ligand. These data will prioritize future screening
of flatworm GPCRs for a (R)-PZQ target and underscore an
activity of (R)-PZQ on 5-HT2BR signaling in the human host,
manifest within the vascular beds where the adult parasites reside.
Results
Mammalian GPCR target(s) of PZQ. Prior work has demon-
strated an ergomimetic like action of PZQ to engage flatworm
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Fig. 3 (R)-PZQ constricts mouse mesenteric vasculature. a Image of mesentery surrounding mouse intestine, showing blood vessel containing a
schistosome worm-pair (inset). b Representative image of a surgically isolated piece of mouse mesenteric artery held under tension between two clamped
wires. Scalebar, 1 mm. c Changes in tension triggered by varied manipulations. Left, sustained contraction of vessels in KPSS and 5-HT (10 µM). Right,
tension in individual arteries incubated in the presence of vehicle (DMSO, open circle) or SB204741 (10 µM, closed circle), and challenged with (R)-PZQ
(50 µM) or (S)-PZQ (50 µM). W, wash; complete media exchange. Preincubation of strips with SB204741 (10 µM) attenuated (R)-PZQ evoked
vasoconstriction. d Cumulative data set from experiments reporting effects of ligands relative to KPS(S)-evoked contractile tension, concentrations of
ligands: 5-HT (1 µM), (R)-PZQ (50 µM), (S)-PZQ (50 µM), SB204741 (10 µM). Replicate number for each measurement as indicated, where individual
measurements reflect the response from a naïve artery isolated from different mice. Data are presented as mean± s.d. Probability, p< 0.05 (*), p< 0.01
(**). e Schematic model (not to scale) depicting (R)-PZQ action on both parasite (contraction) and host vasculature (contraction, increased perfusion
pressure) facilitating hepatic shift of worms
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02084-0
4 NATURE COMMUNICATIONS |8:  1910 |DOI: 10.1038/s41467-017-02084-0 |www.nature.com/naturecommunications
bioaminergic signaling pathways9. Specifically, PZQ exposure
caused a bipolar regeneration phenotype in regenerating free-
living planarian flatworms that was phenocopied by ergot alka-
loids acting as serotonergic antagonists, but opposed by 5-
hydroxytryptamine (5-HT9). Similarly, in both adult schistosome
worms (Supplementary Fig. 1) and schistosomules9, PZQ evoked
a rapid paralysis counteracted by exogenous 5-HT. On the basis
of these observations, we considered whether PZQ acts as a direct
serotoninergic ligand to oppose 5-HT evoked G-protein-coupled
receptor (GPCR) signaling.
To investigate the possibility that PZQ engages serotoninergic
GPCRs, in silico docking approaches were first applied. The resolved
PZQ enantiomers—(R)-PZQ (the active, antischistocidal eutomer,
Fig. 1a) and (S)-PZQ (Fig. 1b)—were screened against a panel of
3436 computational models, representing 1465 protein targets
mostly of human origin, (‘MolScreen’). Both ligands were docked
and scored into ensemble 4D10 models of various targets assembled
in the Pocketome database11. The top candidate from the docking to
pocket classification (‘dpc’ models) was the human 5-HT2B receptor
(5-HT2BR), with (R)-PZQ possessing the highest predicted affinity
(Supplementary Table 1). Figure 1c depicts the orientation of both
(R)-PZQ and (S)-PZQ within the 5-HT2BR orthosteric binding
pocket from modeling simulations. Different binding orientations
for both PZQ enantiomers were predicted with the (R)-isomer
exhibiting a more favorable hydrogen bond with the backbone
amine group of L209 in extracellular loop 2 of 5-HT2BR (Fig. 1c).
With these in silico predictions in hand, we profiled a broad
panel of human GPCRs through the NIMH Psychoactive Drug
Screening Program (PDSP12) first using racemic (±)-PZQ (10
µM) and then the resolved enantiomers ((R)-PZQ and (S)-PZQ13;
Supplementary Fig. 2). (±)-PZQ exhibited a polypharmacological
profile (Supplementary Fig. 3) consistent with predictions from
the in silico modeling data (Fig. 1b). The ability of PZQ to engage
host GPCRs likely explains prior reports of (±)-PZQ action on
heart and smooth muscle14,15, and potentially other known
activities of PZQ such as the bitterness of (S)-PZQ16, a taste
transduced through GPCR signaling. This screen was then
repeated using the individual enantiomers with the criterion for
a positive screening hit defined as stereoselective inhibition of
radioligand binding by (R)-PZQ, but not (S)-PZQ. This was
observed at only one GPCR in the primary screen—the human 5-
HT2B receptor (5-HT2BR)—where inhibition seen with (±)-PZQ
was attributable solely to (R)-PZQ (Fig. 1d, Supplementary Fig. 3).
These data support the in silico modeling, although demonstrate
more biological selectivity for (R)-PZQ over (S)-PZQ at 5-HT2BR.
PZQ interaction with 5-HT2BR was then validated using
radioligand binding and functional assays. Analysis of [3H]-LSD
displacement by (±)-PZQ revealed complete displacement of
specific [3H]-LSD binding at 5-HT2BR by unlabeled (±)-PZQ (Ki
= 5.3 µM, Fig. 1e). For functional activity, Ca2+ flux assays were
performed in HEK293 cells expressing individual 5HT2R isoforms.
(R)-PZQ evoked Ca2+ release in 5-HT2BR expressing cells at
concentrations >1 µM (Fig. 1f). The peak amplitude of (R)-PZQ-
evoked Ca2+ release was consistently less than evoked by 5-HT
(Fig. 1d), suggesting action as a 5-HT2BR partial agonist. No Ca2+
release activity was observed using (S)-PZQ over a comparable
concentration range (Fig. 1f). No Ca2+ release activity was
observed in uninduced cells lacking 5-HT2BR expression, or cells
expressing either 5-HT2AR or 5-HT2CR (Fig. 1f), indicating that
(R)-PZQ activity was specific and selective for the 5-HT2BR. At
other tested GPCRs, including several predicted by the modeling
simulations (Supplementary Table 1), (±)-PZQ lacked Ca2+
release activity (Supplementary Fig. 4).
Further characterization of PZQ-evoked Ca2+ release was
performed in a 5-HT2BR inducible cell line by confocal imaging.
Neither (±)-PZQ, nor 5-HT, evoked cellular Ca2+ transients in
the absence of 5-HT2BR induction, whereas acetylcholine (ACh)
elevated cytoplasmic Ca2+ through endogenous GPCRs (Fig. 2a,
b). Following 5-HT2BR induction, both (±)-PZQ and 5-HT
triggered Ca2+ signals (Fig. 2a, b). Prior incubation of induced
cells with serotonergic blockers ritanserin, SB2047471, or
mesulergine blocked PZQ and 5-HT evoked Ca2+ transients,
but failed to impact ACh-evoked Ca2+ signals (Fig. 2c). Dose-
response relationships revealed (±)-PZQ activity over the
micromolar range (EC50 = 8.1 µM; Fig. 2d) with Ca2+ release
activity solely caused by the (R)-enantiomer (Fig. 2e, f). The 5-
HT2BR blocker LY272015 also inhibited PZQ-evoked Ca2+ signals
(Supplementary Fig. 5).
Next, we examined PZQ-evoked signaling using a transcrip-
tional reporter assay, designed to monitor Ca2+-dependent NFAT
translocation (Supplementary Fig. 6A). In HEK293 cells expres-
sing the reporter construct alone, neither (±)-PZQ nor 5-HT
increased the basal luminescence signal (Supplementary Fig. 6B).
In cells transiently transfected with 5-HT2BR, both PZQ and 5-HT
elicited NFAT translocation and this response was blocked by
ritanserin (Supplementary Fig. 6B). (R)-PZQ activation of NFAT
occurred over the micromolar range (Supplementary Fig. 6C),
again less potent and penetrant than observed with 5-HT (Figs. 1d,
2d). Therefore, multiple experimental approaches demonstrated
(R)-PZQ acted as a partial agonist at human 5-HT2BR.
Action of (R)-PZQ at host GPCRs. These data are significant for
two reasons. First they identify PZQ as a bona fide GPCR ligand
at a defined molecular target. This discovery prioritizes future
screening of flatworm GPCRs (~120 GPCRs in schistosomes17)
for a receptor selectively engaged by (R)-PZQ that could be a key
target for future antischistosomal drug development18,19. Second,
these data suggest PZQ—conventionally viewed as a selective
antiparasitic therapy—can interact with endogenous 5-HT2BRs in
the human host. One pathophysiologically relevant effect would
be an activity of (R)-PZQ on host mesenteric vascular beds, a
destination of the mature, paired adult S. mansoni and S. japo-
nicum blood flukes and sites where egg laying commences2,3
(Fig. 3a). After drug treatment, worms are rapidly displaced from
their mesenteric habitat to the liver where elimination occurs.
This ‘hepatic shift’ is a frequently used assay for drug efficacy and
has been attributed to loss of worm muscle tone evoked by
antischistosomal agents20,21 as seen in vitro (Supplementary
Movie 1). Serotonergic ligands are well known regulators of the
tone of arteries and veins22,23, including mesenteric vessels23,
such that PZQ-evoked changes in mesenteric blood flow may
help ‘flush’ PZQ-paralyzed worms toward the liver. Levels of PZQ
within the splanchnic vasculature likely reach levels an order of
magnitude higher than peak plasma concentrations that are
measured after first-pass metabolism of the drug (>4 µM for
40 mg/kg human dosing, even higher in mouse models24,25).
Therefore, PZQ concentration within mesenteric vessels falls well
within the concentration range for causing host serotonergic
effects demonstrated in vitro (Figs. 1, 2).
The activity of PZQ within the mesenteric vasculature of
uninfected mice was assessed by measuring mesenteric artery
tone using wire myography. Mounted vessel segments (Fig. 3b)
exhibited a rapid, sustained contraction to high K+ media which
reversed upon media exchange (Fig. 3c). Addition of 5-HT to
resting vessel segments also elicited a protracted, contractile
response that declined over time (Fig. 3c). Addition of (R)-PZQ to
naive vessels mimicked the profile of 5-HT evoked contractions
(Fig. 3c), and this effect was prevented by preincubation with
SB204741, a 5-HT2BR antagonist (Fig. 3c). No changes in resting
tone were observed with (S)-PZQ. PZQ also evoked contraction
of hepatic portal vein segments (Supplementary Fig. 7), again
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mimicking 5-HT action26. The cumulative data set demonstrates
(R)-PZQ caused mesenteric artery vasoconstriction, mimicking
the action of 5-HT (Fig. 3d).
In conclusion, we demonstrate that PZQ is a GPCR ligand, with
antischistocidal (R)-PZQ acting as a low micromolar affinity partial
agonist at human 5-HT2B receptors. Activity at both parasite and
host receptors—both targets potentially being GPCRs—likely
contributes to clinical efficacy of PZQ by combining a deleterious
paralytic effect on the parasite (Supplementary Movie 1) with
beneficial host effects that promote worm clearance. We propose
PZQ causes contraction of both the parasite and host mesenteric
vessels to increase perfusion pressure and flush paralyzed worms to
the liver (Fig. 3e). PZQ activity at host 5-HT2BRs may be further
enhanced in individuals infected with chronic schistosomiasis
where pathological changes slow drug elimination24, heighten
serotonergic sensitivity26 and lower basal arteriolar resistance27.
Further, the beneficial effects of host GPCR engagement may
extend beyond the vasculature given a role for 5HT2BRs in
regulating inflammation, liver fibrosis and regeneration: all out-
comes relevant to chronic schistosomiasis pathology28,29. In
conclusion, these data support a strategy for developing novel
anthelmintics with cross species polypharmacology to reinforce
disease mitigating actions in both host and parasite.
Methods
Reagents. Ritanserin, SB204741 and mesulergine were from Tocris Bioscience. All
other ligands were from Sigma-Aldrich. Cell culture reagents were from Invitrogen.
PZQ enantiomers ((R)-[-]PZQ and (S)-[+]PZQ) were resolved (Supplementary
Fig. 2) using methods published by Woelfle et al.13.
Mammalian GPCR profiling. PZQ (racemic and enantiomers) were screened
against human GPCRs using primary and secondary assays coordinated through the
NIMH Psychoactive Drug Screening Program (PDSP). Full details describing these
methods are available in the PDSP Assay Protocol Book available online (https://
pdspdb.unc.edu/pdspWeb/). PZQ was dissolved in 100% ethanol at a concentration
of 100mM to achieve a maximal assay concentration (up to 100 µM) for both
binding and functional assays. Ca2+ flux experiments utilized tetracycline-inducible
stable cell lines for 5HT2A, 5HT2B, and 5HT2C receptors initially generated using the
Flp-In 293 T-REx tetracycline inducible system30 (a gift from the Roth Lab, Invi-
trogen). Cells were maintained in DMEM (ThermoFisher, 10569010) supplemented
with 10% dialyzed fetal bovine serum (Gibco, 26400044), 50 U/mL Penicillin-
Streptomycin (ThermoFisher Scientific, 15140122), 10 µg/ml Blasticidin (Research
Products International, B12150-0.1) and 100 µg/ml Hygromycin B (ThermoFisher
Scientific, 10687010) at 37 °C and 5% CO2. For Ca2+ flux assays, receptor expression
was induced with 2 µg/mL tetracycline, and cells were plated into white 384 clear
bottom, tissue culture plates in 40 μL of DMEM containing 1% dialyzed FBS at a
density of ~15,000 cells per well the day before the assay. Next day, media was
decanted and 20 µL per well of Fluo-4 Direct dye (Invitrogen) was added and
incubated for 1 h at 37 °C. The cells were stimulated with test compounds diluted in
drug buffer (HBSS, 20mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) and
calcium flux was measured using a FLIPRTETRA (Molecular Devices). Plates were
read for fluorescence initially for 10 s (1 read per second) to establish a baseline, and
then stimulated with drug dilutions or buffer and read for an additional 110 s. Peak
fluorescence in each well was normalized to maximum-fold increase over baseline.
The data were normalized to maximum peak fold over basal fluorescence by 5-HT
(100%) and baseline fluorescence (0%). The data were analyzed using the sigmoidal
dose-response function built into GraphPad Prism 5.0.
In silico modeling. (R)-PZQ and (S)-PZQ were screened against a panel of 3436
computational models designed to predict activities of arbitrary chemical com-
pounds, representing 1465 proteins targets mostly of human origin (so called
‘MolScreen’ panel). The earlier version of this set of models that included different
classes of targets31 described and validated the panel. Two main types of three
dimensional docking models were used: ‘dpc’ models (349 models representing the
conformational ensembles of binding pocket conformations from the Pocketome
database11) and ‘dfa’ models (pharmacophoric field models based on the con-
tinuous three dimensional pharmacophoric fields of the diverse co-crystallized
ligands from the Pocketome database, enhanced by training on the activity data
from the ChEmbl database32,33).
Confocal Ca2+ imaging. For single-cell confocal Ca2+ imaging, the 5HT2B indu-
cible cell line was seeded onto collagen-coated, 35 mm glass bottom dishes (Mat-
Tek, P35GCOL-0-14-C) at a density of 1 × 104 cells three days prior to imaging.
Two days prior to imaging, 5-HT receptor expression was induced by
supplementing the growth media with 1 µg/ml doxycycline (Sigma-Aldrich,
D3447). Two hours prior to conducting experiments, growth medium was
exchanged for EMEM supplemented with 1% dialyzed FBS, plus antibiotics. The
cells were washed twice with Hank’s balanced salt solution (HBSS), and incubated
with Fluo-4-AM (4 µM) and Pluronic F127 (0.4%) for 25 minutes at room tem-
perature. The cells were then washed twice with HBSS, and left at room tem-
perature (30 min) for de-esterification. Dishes were mounted on an Olympus IX81
microscope and fluorescence changes (λex = 488 nM, (λem = 513± 15 nm bandpass)
monitored using a Yogokawa spinning disk confocal (CSU-X-M1N) and an Andor
iXon Ultra 888 EMCCD camera. HEK293 cell lines were sourced from ATCC
(CRL-1573) and found to be negative for mycoplasma contamination.
Wire myography. Swiss Webster mice (female, aged 10–13 weeks) were obtained
from Charles River Laboratories. Measurements of mouse mesenteric vessel tone
were made using a multimyograph system (DMT, Aarhus, Denmark). Vessel strips
were isolated from second order mesenteries and equilibrated for ≥30 min in
gassed (95% O2, 5% CO2), physiological saline solution (PSS, 130 mM NaCl,
4.7 mM KCl, 1.18 mM KH2PO4, 1.17 mM MgSO4, 14.9 mM NaHCO3, 5.5 mM
dextrose, 0.026 mM EDTA, 1.6 mM CaCl2, pH 7.4 at 37 °C). To identify the
optimal pre-stretch value for experiments, a normalization factor (IC1/IC100) was
calculated for individual test strips34,35, defined as the ratio of the internal cir-
cumference at which the maximum response to vasoconstriction (KCl, plus 40 µM
norepinephrine) was observed (IC1), divided by the internal circumference at
which a transmural wall pressure of 100 mm of Hg is attained on a length-tension
plot overlayed with a La Place transformation isobar (IC100). After vessel equili-
bration, reactivity was measured under isometric conditions in response to KCl
(KPSS, 74.7 mM NaCl, 60 mM KCl, 1.18 mM KH2PO4, 1.17 mM MgSO4, 14.9 mM
NaHCO3, 5.5 mM dextrose, 0.026 mM EDTA, 1.6 mM CaCl2, pH 7.4 at 37 °C) or
indicated ligands, as per published protocols. All animal experiments followed
ethical regulations approved by the University of Minnesota IACUC committee
and reviewed by the National Institutes of Health (NIAID).
Adult Schistosoma mansoni mobility assays. Infected mice were provided by the
Biomedical Research Institute (33) from which adult worms were collected by portal
perfusion 6–8-week-post infection. Mobility experiments were conducted 24–48 h
after worm collection using a compound microscope equipped with a digital video
camera to acquire video recordings (3 frames per second for 1–2min) of worms
exposed to various drugs. Analysis was performed in ImageJ after file import using the
Bio-Formats plugin. Differences in illumination were corrected using the stack
deflicker function of the wrMTrck plugin. Images were processed by converting to
binary format, and mobility was assayed by measuring the average difference in pixels
resulting from subtracting two consecutive frames, providing a measurement of the
worms displacement over that period (~0.3 s). This calculation was performed for
each frame in the video, and the results were averaged over the length of the recording
to provide a metric of worm movement. Unless otherwise noted, values reported
represent the mean± standard error of at least three independent experiments.
Mammalian GPCR profiling. Primary GPCR screening assays were coordinated
through the NIMH Psychoactive Drug Screening Program (PDSP). Methods and
statistical analyzes for radioligand binding and functional assays are available in the
PDSP Assay Protocol Book available online (https://pdspdb.unc.edu/pdspWeb/).
Ca2+ flux assays were performed as similarly described, except experiments utilized
muscarinic M1, M3, M5 receptors stably expressed in CHO cells. For experiments
measuring cAMP, experiments utilized co-transfection with the cAMP split-
luciferase reporter GloSenso(R)-22F plasmid (Promega, 1:1 ratio with receptor)
and were read for luminescence on a TriLux Microbeta (Perkin Elmer). For Gi/o
mediated cAMP inhibition, forskolin (1 µM) was used to stimulate cAMP via
adenylyl cyclase activation.
NFAT reporter assay. The Ca2+ sensitive transcriptional luciferase reporter
pGL4.30[luc2P/NFAT-RE/Hygro] (Promega, E8481) was transiently transfected
into the 5HT2BR stable cell line. Briefly, 3 × 106 cells were plated in a Nunc Cell
Culture Treated flask (25 cm2, ThermoFisher) and transfected with lipofectamine
2000 (ThermoFisher) plus 1 µg of plasmid DNA according to the manufacturer’s
protocol. The following day, culture media was replaced with induction media
(DMEM + 10% dialyzed FBS supplemented with 1 µg/ml doxycycline), and 24 h
later cells were re-plated into 96 well, solid white plates (Costar, 3917). After
allowing 3 h for cells to adhere, drugs were added at 20× concentration. For
antagonist experiments, cells were incubated with 5HT2B R antagonists for 2 h
prior to subsequent addition of agonist. After 18 h culture in the presence of
agonist, plates were assayed using the ONE-Glo Luciferase Assay System (Promega,
E6120) and read on a GloMax-Multi Detection System plate reader (Promega).
Statistical analysis. Except for the myography experiments, data (PDSP data,
confocal calcium imaging) were analyzed using the two tailed Student’s t-test, and
are reported except where explicitly indicated as mean ± s.e.m for independent
biological replicates (defined as independent transfections or inductions). For
myography experiments, where the amounts of resolved enantiomers were limiting,
measurements were made in vessels isolated from 3–6 mice, a sample size
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providing a α-significance criterion of 0.05 and a β of 0.9. No randomization or
blinding was used in the animal studies, as no comparative analyzes were involved.
The statistical significance between experimental groups in myography experi-
ments was determined using the Mann–Whitney test and data are presented as
mean± s.d. for these assays. Replicate numbers for individual experiments are
outlined within Figure Legends or Figures as appropriate for clarity. Probability
values of p< 0.05 were considered statistically significant.
Data availability. The authors declare that the data supporting the findings of this
study are available within the paper and its Supplementary Data Files or from the
corresponding author on reasonable request.
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